Reliant acquires Abbott’s Rythmol
Executive Summary
Reliant Pharmaceuticals acquires antiarrhythmic Rythmol product family from Abbott Labs. Reliant already markets the statin Lescol and the calcium channel blocker DynaCirc under an agreement with Novartis. With the Rythmol addition, Reliant plans to increase the size of its sales force to more than 900 reps. Rythmol SR (propafenone sustained-release) was approved by FDA Sept. 4...